Frontpro (previously known as Afoxolaner Merial)

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

afoxolaner

Available from:

Boehringer Ingelheim Vetmedica GmbH

ATC code:

QP53BE01

INN (International Name):

afoxolaner

Therapeutic group:

Psi

Therapeutic area:

Ektoparaziticidi za sistemsko uporabo

Therapeutic indications:

Zdravljenje bolh (Ctenocephalides felis in C. canis) infestations. Izdelek se lahko uporablja kot del strategije zdravljenja za nadzor alergijskega dermatitisa bolha (FAD). Zdravljenje klopi (Dermacentor reticulatus, Ixodes ricinus, Rhipicephalus sanguineus) infestations. Zdravljenje demodicosis (zaradi Demodex canis). Zdravljenje sarcoptic mange (zaradi Sarcoptes scabiei var. canis).

Product summary:

Revision: 3

Authorization status:

Pooblaščeni

Authorization date:

2019-05-20

Patient Information leaflet

                                15
B. NAVODILO ZA UPORABO
16
NAVODILO ZA UPORABO
FRONTPRO 11 MG ŽVEČLJIVE TABLETE ZA PSE 2–4 KG
FRONTPRO 28 MG ŽVEČLJIVE TABLETE ZA PSE >4–10 KG
FRONTPRO 68 MG ŽVEČLJIVE TABLETE ZA PSE >10–25 KG
FRONTPRO 136 MG ŽVEČLJIVE TABLETE ZA PSE >25–50 KG
1.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM TER
PROIZVAJALEC ZDRAVILA, ODGOVOREN ZA SPROŠČANJE SERIJ, ČE STA
RAZLIČNA
Imetnik dovoljenja za promet z zdravilom:
Boehringer Ingelheim Vetmedica GmbH
55216 Ingelheim/Rhein
NEMČIJA
Proizvajalec, odgovoren za sproščanje serij:
Boehringer Ingelheim Animal Health France SCS
4 Chemin du Calquet
31000 Toulouse
Francija
2.
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI
FRONTPRO 11 mg žvečljive tablete za pse 2–4 kg
FRONTPRO 28 mg žvečljive tablete za pse >4–10 kg
FRONTPRO 68 mg žvečljive tablete za pse >10–25 kg
FRONTPRO 136 mg žvečljive tablete za pse >25–50 kg
afoksolaner
3.
NAVEDBA UČINKOVIN(E) IN DRUGE(IH) SESTAVIN
Vsaka tableta vsebuje:
FRONTPRO
AFOKSOLANER (MG)
Žvečljive tablete za pse 2 ̶ 4 kg
11,3
Žvečljive tablete za pse >4 ̶
10 kg
28,3
Žvečljive tablete za pse >10 ̶ 25 kg
68
Žvečljive tablete za pse >25 ̶ 50 kg
136
Lisaste rdeče ali rdeče-rjave, okrogle (tablete za pse 2–4 kg) ali
pravokotne tablete (tablete za pse
> 4-10 kg, tablete za pse >10–25 kg in tablete za pse >25–50 kg).
4.
INDIKACIJA(E)
Zdravljenje infestacije z bolhami pri psih (
_Ctenocephalides felis _
and
_ C. canis_
) vsaj 5 tednov. Zdravilo
je lahko del strategije zdravljenja in preprečevanja alergijskih
dermatitisov, ki jih povzroča bolhavost
(FAD).
Zdravljenje infestacije s klopi pri psih (
_Dermacentor reticulatus, Ixodes ricinus, Rhipicephalus _
_sanguineus). _
Eno zdravljenje ubija klope do 1 mesec.
Da pride do izpostavljenosti učinkovini, se morajo bolhe in klopi
pritrditi na gostitelja in pričeti s
hranjenjem.
17
Zdravljenje demodikoze (ki jo povzroča
_Demodex canis_
).
Zdravljenje garjavosti (ki jo povzroča
_Sarcoptes scabiei var. canis_
).
5.
KONTRAINDIKACIJE
Ne uporab
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI
FRONTPRO 11 mg žvečljive tablete za pse 2–4 kg
FRONTPRO 28 mg žvečljive tablete za pse >4–10 kg
FRONTPRO 68 mg žvečljive tablete za pse >10–25 kg
FRONTPRO 136 mg žvečljive tablete za pse >25–50 kg
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Vsaka žvečljiva tableta vsebuje:
UČINKOVINA:
FRONTPRO
AFOKSOLANER (MG)
Žvečljive tablete za pse 2 ̶ 4 kg
11,3
Žvečljive tablete za pse >4 ̶
10 kg
28,3
Žvečljive tablete za pse >10 ̶ 25 kg
68
Žvečljive tablete za pse >25 ̶ 50 kg
136
Za celoten seznam pomožnih snovi, glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
Žvečljive tablete.
Lisaste rdeče ali rdeče-rjave, okrogle (tablete za pse 2–4 kg) ali
pravokotne tablete (tablete za pse
>4-10 kg, tablete za pse >10–25 kg in tablete za pse >25–50 kg).
4.
KLINIČNI PODATKI
4.1
CILJNE ŽIVALSKE VRSTE
Psi.
4.2
INDIKACIJE ZA UPORABO PRI CILJNIH ŽIVALSKIH VRSTAH
Zdravljenje infestacije z bolhami pri psih (
_Ctenocephalides felis _
and
_ C. canis_
) vsaj 5 tednov. Zdravilo
je lahko del strategije zdravljenja in preprečevanja alergijskih
dermatitisov, ki jih povzroča bolhavost
(FAD).
Zdravljenje infestacije s klopi pri psih (
_Dermacentor reticulatus, Ixodes ricinus, Rhipicephalus _
_sanguineus). _
Eno zdravljenje ubija klope do 1 mesec.
Da pride do izpostavljenosti učinkovini, morajo bolhe in klopi priti
v stik z gostiteljem in
pričeti s hranjenjem.
Zdravljenje demodikoze (ki jo povzroča
_Demodex canis_
).
Zdravljenje garjavosti (ki jo povzroča
_Sarcoptes scabiei var. canis_
).
4.3
KONTRAINDIKACIJE
Ne uporabite v primerih preobčutljivosti na učinkovino ali na katero
koli pomožno snov.
3
4.4
POSEBNA OPOZORILA ZA VSAKO CILJNO ŽIVALSKO VRSTO
Paraziti se morajo začeti hraniti, da pridejo v stik z afoksolanerom,
zato prenosa s paraziti prenosljivih
bolezni ni mogoče izključiti.
4.5
POSEBNI PREVIDNOSTNI UKREPI
Posebni previdnostni ukrepi za uporabo pri živalih
Ker ni razpoložljivih podatkov, mora 
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 12-11-2020
Summary of Product characteristics Summary of Product characteristics Bulgarian 12-11-2020
Public Assessment Report Public Assessment Report Bulgarian 12-11-2020
Patient Information leaflet Patient Information leaflet Spanish 12-11-2020
Public Assessment Report Public Assessment Report Spanish 12-11-2020
Patient Information leaflet Patient Information leaflet Czech 12-11-2020
Public Assessment Report Public Assessment Report Czech 12-11-2020
Patient Information leaflet Patient Information leaflet Danish 12-11-2020
Public Assessment Report Public Assessment Report Danish 12-11-2020
Patient Information leaflet Patient Information leaflet German 12-11-2020
Public Assessment Report Public Assessment Report German 12-11-2020
Patient Information leaflet Patient Information leaflet Estonian 12-11-2020
Public Assessment Report Public Assessment Report Estonian 12-11-2020
Patient Information leaflet Patient Information leaflet Greek 12-11-2020
Public Assessment Report Public Assessment Report Greek 12-11-2020
Patient Information leaflet Patient Information leaflet English 12-11-2020
Public Assessment Report Public Assessment Report English 12-11-2020
Patient Information leaflet Patient Information leaflet French 12-11-2020
Public Assessment Report Public Assessment Report French 12-11-2020
Patient Information leaflet Patient Information leaflet Italian 12-11-2020
Public Assessment Report Public Assessment Report Italian 12-11-2020
Patient Information leaflet Patient Information leaflet Latvian 12-11-2020
Public Assessment Report Public Assessment Report Latvian 12-11-2020
Patient Information leaflet Patient Information leaflet Lithuanian 12-11-2020
Summary of Product characteristics Summary of Product characteristics Lithuanian 12-11-2020
Public Assessment Report Public Assessment Report Lithuanian 12-11-2020
Patient Information leaflet Patient Information leaflet Hungarian 12-11-2020
Summary of Product characteristics Summary of Product characteristics Hungarian 12-11-2020
Public Assessment Report Public Assessment Report Hungarian 12-11-2020
Patient Information leaflet Patient Information leaflet Maltese 12-11-2020
Public Assessment Report Public Assessment Report Maltese 12-11-2020
Patient Information leaflet Patient Information leaflet Dutch 12-11-2020
Public Assessment Report Public Assessment Report Dutch 12-11-2020
Patient Information leaflet Patient Information leaflet Polish 12-11-2020
Public Assessment Report Public Assessment Report Polish 12-11-2020
Patient Information leaflet Patient Information leaflet Portuguese 12-11-2020
Summary of Product characteristics Summary of Product characteristics Portuguese 12-11-2020
Public Assessment Report Public Assessment Report Portuguese 12-11-2020
Patient Information leaflet Patient Information leaflet Romanian 12-11-2020
Public Assessment Report Public Assessment Report Romanian 12-11-2020
Patient Information leaflet Patient Information leaflet Slovak 12-11-2020
Public Assessment Report Public Assessment Report Slovak 12-11-2020
Patient Information leaflet Patient Information leaflet Finnish 12-11-2020
Public Assessment Report Public Assessment Report Finnish 12-11-2020
Patient Information leaflet Patient Information leaflet Swedish 12-11-2020
Public Assessment Report Public Assessment Report Swedish 12-11-2020
Patient Information leaflet Patient Information leaflet Norwegian 12-11-2020
Summary of Product characteristics Summary of Product characteristics Norwegian 12-11-2020
Patient Information leaflet Patient Information leaflet Icelandic 12-11-2020
Summary of Product characteristics Summary of Product characteristics Icelandic 12-11-2020
Patient Information leaflet Patient Information leaflet Croatian 12-11-2020
Public Assessment Report Public Assessment Report Croatian 12-11-2020

Search alerts related to this product